SCHEMBL29484068

SCHEMBL29484068

COC(=O)[C@@H](NC(=O)[C@H](CN)NC(=O)OC(C)(C)C)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PSENEN Q9NZ42 9/20 0.47
▸ CTSD P07339 4/20 0.47
▸ CTSS P25774 3/20 0.47
▸ CTSK P43235 3/20 0.47
▸ PSEN1 P49768 8/20 0.46
▸ PSEN2 P49810 8/20 0.46
▸ APH1B Q8WW43 8/20 0.46
▸ NCSTN Q92542 8/20 0.46
▸ APH1A Q96BI3 8/20 0.46
▸ KLK5 Q9Y337 1/20 0.45
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ REN P00797 1/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484061 0.88 PSENEN (0.55) PSENENCTSDCTSSCTSKCA2
SCHEMBL23080079 0.87 PSENEN (0.48) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL30910781 0.86 BACE1 (0.49) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL22989798 0.84 CTSD (0.44) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL10144106 0.83 PSENEN (0.45) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL7104010 0.82 PSENEN (0.59) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL2548149 0.82 PSENEN (0.59) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL17137934 0.82 PSENEN (0.59) PSENENCTSDCTSSCTSKPSEN1
SCHEMBL8238351 0.82 CYP1A2 (0.46) CTSSCTSKKLK5CA1CA2
SCHEMBL1770995 0.82 CYP1A2 (0.46) CTSSCTSKKLK5CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612429-B2 Derivatives of dolaproine-dolaisoleuine peptides AGENSYS, INC. (US) 2026-04-28 — — US disclosed
US-20220204557-A1 DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES AGENSYS, INC. (US) 2022-06-30 — — US disclosed
US-11312748-B2 Derivatives of dolaproine-dolaisoleucine peptides AGENSYS, INC. (US) 2022-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204557-A1 DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES DDOST, VIP, THPO PSENEN 3639/4885CTSD 2926/4885CTSS 3180/4885
US-12612429-B2 Derivatives of dolaproine-dolaisoleuine peptides DDOST, NGLY1, GRPR PSENEN 4087/4885CTSD 3879/4885CTSS 2592/4885
US-11312748-B2 Derivatives of dolaproine-dolaisoleucine peptides VIP, DDOST, DNPEP PSENEN 3625/4885CTSD 3965/4885CTSS 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback